MARKET

KRTX

KRTX

Karuna Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

99.75
0.00
0.00%
After Hours: 100.00 +0.25 +0.25% 19:46 01/24 EST
OPEN
100.14
PREV CLOSE
99.75
HIGH
102.42
LOW
97.00
VOLUME
933.22K
TURNOVER
--
52 WEEK HIGH
152.00
52 WEEK LOW
11.24
MARKET CAP
2.13B
P/E (TTM)
-50.0627
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KRTX News

  • Karuna Therapeutics down 18% on stock sale
  • seekingalpha.3d ago
  • Why Karuna Therapeutics Shares Sank Today
  • MotleyFool.com.3d ago
  • Karuna Therapeutics Shares Tick Slightly Higher As Hearing William Blair Sees 'Significant Buying Opportunity' In Stock, Notes Unique Position Of Co.'s KarXT Antipsychotic Treatment; Highlights $105 Fair Value, Notes $175 Potential Value In Takeover
  • Benzinga.3d ago
  • Wells Fargo Maintains Overweight on Karuna Therapeutics, Raises Price Target to $137
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About KRTX

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.
More

Webull offers Karuna Therapeutics Inc (KRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.